SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
Trump Says Anthropic No Longer Seen as National Security Threat 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
Oracle Cuts 21,000 Jobs as AI Reshapes Workforce and Cloud Expansion Accelerates 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
WINTER SPRINGS, Fla., Jan. 28, 2016 -- IRADIMED CORPORATION (NASDAQ:IRMD) announced today that its Board of Directors has approved a stock repurchase program, authorizing the repurchase of up to $10 million of the Company’s common stock through January 28, 2017.
The Company intends to use cash on hand, investments and cash generated from operations to fund the share repurchase program. As of December 31, 2015, the Company had cash, cash equivalents and investments of approximately $27 million.
The timing and amount of the repurchases will be subject to applicable legal requirements including federal and state securities laws. Purchases will be made in open market transactions effected through a broker-dealer at prevailing market prices, in block trades, or in privately negotiated transactions. Any repurchased shares will be available for general corporate purposes.
About IRADIMED CORPORATION
IRADIMED CORPORATION is the only known provider of non-magnetic intravenous (“IV”) infusion pump systems that are specifically designed to be safe for use during magnetic resonance imaging (“MRI”) procedures. We were the first to develop an infusion delivery system that neutralizes the dangers and problems present during MRI procedures. Standard infusion pumps contain magnetic and electronic components which can create radio frequency (“RF”) interference and are dangerous to operate in the presence of the powerful magnet that drives an MRI system. Our MRidium MRI compatible IV infusion pump system has been designed with a patented non-magnetic ultrasonic motor, uniquely-designed non-ferrous parts and other special features in order to safely and predictably deliver anesthesia and other IV fluids during various MRI procedures. Our pump solution provides a seamless approach that enables accurate, safe and dependable fluid delivery before, during and after an MRI scan, which is important to critically-ill patients who cannot be removed from their vital medications, and children and infants who must generally be sedated in order to remain immobile during an MRI scan.
Media Contact: Chris Scott Chief Financial Officer IRADIMED CORPORATION (407) 677-8022 [email protected]
